Recently, the gene editing company Boya Eingen (EdiGene) recently announced the completion of 100 million yuan Pre-B round of financing. This round of financing was led by Lilly Asia Fund, Huagai Capital and investment, and A-round investors such as IDG Capital, China Economic Cooperation and Gong Hongjia followed suit. Previously, Boyaa series received a $10 million Series A financing from IDG in October 2016.
Founded in 2015, EdiGene is a national high-tech enterprise headquartered in Beijing with branches in Guangzhou and Cambridge, USA. Ranked as a technology-intensive start-up for 2017 by capital, the top biotechnology journal Nature Biotechnology. EdiGene uses genome editing technology to establish stable partnerships with hospitals and clinicians to develop new therapies for diseases that are currently difficult to cure. EdiGene has developed a treatment for a variety of hereditary diseases and tumors, and the first therapeutic product is expected to be the world's first genetically edited cell therapy product to enter the clinical stage.
EdiGene has a high-throughput genetic screening technology based entirely on proprietary intellectual property rights that can rapidly target disease targets for drug and therapy development. Up to now, Boya has won dozens of awards and certifications such as the China Patent Excellence Award, the Overseas Students' Entrepreneurship Enterprise with the greatest growth potential of the Ministry of Human Resources and Social Security, the National High-Tech Enterprise, and the Zhongguancun Golden Seed Enterprise. EdiGene's gene editing therapy is divided into two types, in vitro and in vivo. Among them, ET-01, which is the fastest in the treatment of beta thalassemia, is a CRISPR-based gene editing therapy for the treatment of beta thalassemia. The therapeutic principle of this therapy is to compensate for the deficiency of normal beta hemoglobin by increasing the patient's fetal hemoglobin level. Preclinical studies have demonstrated the feasibility of this approach. At present, EdiGene's GMP production workshop and related facilities for the ET-01 project have been built in Guangzhou. The project is expected to take the lead in entering the clinical research phase in 2019.
Founder Dr. Wei Wensheng is a researcher at Peking University, deputy director of the Genetics Society of the Genetic Society, and an expert on the CDE Drug Registration Review Expert Committee. He holds a Ph.D. from the University of Michigan, a postdoctoral degree from Stanford University, and a bachelor's degree from Peking University. His published article has a total impact factor of more than 280, with more than nine articles published in Nature, Cell, and its publications. Has a number of invention patents. He is a judge of international academic journals such as Nature, Nature Reviews, Nature Biotechnology and Molecular Cell Biology, and has won many honors including China Patent Excellence Award, Science China (2015) Person of the Year, Tanjiatun Life Science Innovation Award, etc. Ministry of Science and Technology “2017 Innovative Talent Promotion Planâ€.
“The company’s gene editing and treatment program has great potential, and this financing can provide sufficient funds for the next step of the company’s genetic editing treatment project,†said Dr. Wei Dong, CEO of Boya, “In addition, based on continuous accumulation of technological innovation and autonomy. Intellectual property, we will develop a more comprehensive and comprehensive high-throughput genetic screening program to meet the needs of customers in the screening of drugs for drug sensitivity, drug resistance and synthetic lethality."
“We are very excited to be able to invest in the Boyaa series,†said Dr. Chen Fei, Lilly Asia Fund Management Partner. “Gene editing technology has made breakthroughs in disease treatment and drug development. We are very happy to work with the Boya Collection team. Collaborate and support its global development."
“I am very pleased that I can get a short-term fund and quickly push the company to the next stage. This round of financing introduces new capital such as Lilly Asia, as well as the original shareholders and directors who know the company’s operations. With investment, this shows that the capital market's interest and recognition of the company is an affirmation of the company's work in recent years, and is also a conviction of the company's future potential." Dr. Wei Wensheng, founder of Boya Collection, said: "We are very looking forward to Lilly Asia. The fund and other investors work together to push the company's product lines forward and further to cure the patients.†Dr. Wei Wensheng, founder of Boya, said: “We look forward to working with Lilly Asia Fund and other investors. Together to promote the company's product line forward, and further to the final cure of patients."
Introduction:
The bulb of garlic,an allium plant in the lily family.with the pungent flavor and spicy taste.spherical shape with a diameter of 3-6.5cm. The surface is covered with white and papery-skin.
The top is slightly pointed, with residual scape in the middle,many fibrous root marks at the base. After peeling off the skin, a single head or 6 to 16 petal-shaped small bulbs, inserted around the base of the remaining flower stems. The bulbous valve is slightly ovoid, with a membranous outer skin, slightly pointed at the apex, and an arcuate bulge on one side.
In order to ensure the maximum freshness and nutrients.
We adhere to the traditional natural drying method without any human intervention.
The garlic cultivated and planted according to ecological standards.without the use of chemical agents, the pesticide residues reach the export standards.
Can be stored for long time under proper conditions after sun drying.
With the characteristics of big size,white&distinct appearance,pure flavor,pure flavor,crispy taste,high capsaicin.
Specification
Brand:Changrong
Variety:Liliaceous Vegetables
Color:Purple red
Organic Red Garlic,Red Garlic Seed,Organic Red Garlic Seed,Fresh Organic Red Garlic Cloves
shandong changrong international trade co.,ltd. , https://www.cragriculture.com